Bruton’s Kinase Inhibitors for the Treatment of Immunological Diseases: Current Status and Perspectives

The use of Bruton’s tyrosine kinase (BTK) inhibitors has changed the management of patients with B-cell lymphoid malignancies. BTK is an important molecule that interconnects B-cell antigen receptor (BCR) signaling. BTK inhibitors (BTKis) are classified into three categories, namely covalent irrever...

Descripción completa

Detalles Bibliográficos
Autores principales: Robak, Ewa, Robak, Tadeusz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9145705/
https://www.ncbi.nlm.nih.gov/pubmed/35628931
http://dx.doi.org/10.3390/jcm11102807

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9145705/
https://www.ncbi.nlm.nih.gov/pubmed/35628931
http://dx.doi.org/10.3390/jcm11102807

Ejemplares similares